Operates as a pharmaceutical contract development and manufacturing organisation (CDMO) with four pillars: drug-device combinations (DDC), biologics, soft gelatin capsules, and sterile injectables. The DDC business fills pen cartridges for generic semaglutide, holding more than 40% of the generic pen market sold in India as of June 26, 2026, with all three Canadian semaglutide approvals held by the company. DDC cartridge line is 100% utilised; a second cartridge line was commercialising in Q1 FY27, a third is planned within FY27 and a fourth in FY28, expanding sterile-cartridge days from about 225 in FY27 to about 475 in FY28. Biologics provides integrated drug substance and drug product manufacturing from its Bangalore site; customers include Formycon AG (biosimilars) and two US tirzepatide first-to-file customers, with the RFP funnel stated to be roughly four times the year-ago level. Soft gelatin capacity of 2.4 billion units is transitioning from captive Strides use to a full CDMO model, with a greenfield expansion planned. Sterile injectables are being expanded via a Q2-Q3 FY27 site shutdown to add lyophilisation and pre-filled syringe capability. Q1 FY27 revenue was INR 4,490 million (+37% YoY) and EBITDA INR 1,233 million (about 27.5% margin). FY28 guidance is US$400 million organic revenue and 40% EBITDA margin. The company runs five manufacturing facilities approved by the US FDA and EMA and has over 1,600 professionals; a US$100 million capex programme is in flight, with about 80% committed as of Q1 FY27. The biggest opex line is materials at 30.7% of FY26 revenue, followed by depreciation at 19.6% (reflecting the asset-heavy build-out), employees at 17.0% and other opex at 30.3%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Drug-device combinations (DDC), Biologics CDMO, Soft gelatin capsules, Sterile injectables. Asset-heavy pharmaceutical CDMO with ongoing multi-site capacity expansion
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 1,445 | 1,422 |
| EBITDA (ex other income) | 356 | 294 |
| margin % | 24.6 | 20.7 |
| Owners' profit | (18) | (74) |
| EPS, as reported (₹) | (1.63) | (6.44) |
| ROE % · ROCE % | (0.3) · 1.5 | (1.3) · 0.4 |
| Debt / equity (x) | 0.13 | 0.22 |
| Cash from operations | (22) | 9 |
| Capex | 0 | (569) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 68 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| Profit before tax | (39) | (67) | 84 | (4) | 6 | (93) | (0) | 20 |
| Net profit | (39) | (69) | 98 | (0) | 10 | (89) | 5 | 25 |
| EPS (₹) | (18.82) | (6.31) | 8.61 | (0.02) | 0.92 | (7.74) | 0.40 | 2.18 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Addendum to 19th AGM notice for September 23, 2026 | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Investor Presentation uploaded post analyst meet | investor communications | medium | — | — |
| 1 Sept 2026 · Newspaper ad confirming dispatch of 19th AGM notice and e-voting details | compliance | minimal | — | — |
| 31 Aug 2026 · OneSource Specialty Pharma files BRSR for FY26 under SEBI norms | compliance | low | — | — |
| 31 Aug 2026 · AGM on Sep 23, 2026; FY26 annual report released | board shareholder meetings | low | — | — |
| 31 Aug 2026 · OneSource schedules group investor meeting on Sep 3 at Unit 2 facility | board shareholder meetings | low | — | — |
| 29 Aug 2026 · Newspaper ad published for 19th AGM on September 23, 2026 | compliance | minimal | — | — |
| 29 Aug 2026 · OneSource Specialty Pharma informs exchanges about 19th AGM newspaper notice | compliance | minimal | — | — |
| 18 Aug 2026 · Credit rating upgraded to IND A with Positive Outlook by Ind-Ra | credit debt | medium | — | — |
| 31 Jul 2026 · Q1 FY27 earnings call transcript; FY28 guidance of 400M dollar revenue, 40% EBITDA margin reiterated | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 3.1 | 3.3 | 78 of 163 | 53% |
| ROCE | (1.4) | 10.8 | 156 of 183 | 15% |
| ROE | (1.3) | 10.4 | 151 of 171 | 12% |
| Debt / Equity | 0.2 | 0.1 | 105 of 171 | 39% |
| EBITDA margin | 27.4 | 17.5 | 42 of 165 | 75% |
| Revenue growth | 37.2 | 16.3 | 32 of 161 | 81% |
| Profit growth | 13539.3 | 30.9 | 1 of 158 | 100% |
| Market cap | 18250 | 839 | 31 of 182 | 83% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
